Retatrutide: a triple incretin receptor agonist for obesity management
Expert Opin Investig Drugs. 2023 Oct 30:1-6. doi: 10.1080/13543784.2023.2276754. Online ahead of print.ABSTRACTINTRODUCTION: Obesity treatment is evolving rapidly with the emergence of agents targeting incretin receptors. Retatrutide, a triple agonist of these receptors, shows promise in obesity management.AREAS COVERED: Retatrutide, in phase-2 trials, exhibited significant reductions in glycated hemoglobin (HbA1c) and dose-dependent weight loss in individuals with type 2 diabetes mellitus (T2DM). In non-T2DM individuals, it produced substantial weight loss and improved glucose levels, albeit with gastrointestinal side eff...
Source: Expert Opinion on Investigational Drugs - October 30, 2023 Category: Drugs & Pharmacology Authors: Avik Ray Source Type: research
Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
Glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 are the main incretin hormones, and be responsible for the insulinotropic incretin effect. The addition of a GIP agonist to a GLP-1agonist has been ... (Source: Diabetology and Metabolic Syndrome)
Source: Diabetology and Metabolic Syndrome - October 30, 2023 Category: Endocrinology Authors: Qian Zhou, Xingxing Lei, Shunlian Fu, Pan Liu, Cong Long, Yanmei Wang, Zinan Li, Qian Xie and Qiu Chen Tags: Review Source Type: research
Novel Approaches for the Management of Type 2 Diabetes Mellitus: An Update
Curr Diabetes Rev. 2023 Oct 5. doi: 10.2174/0115733998261903230921102620. Online ahead of print.ABSTRACTDiabetes mellitus is an irreversible, chronic metabolic disorder indicated by hyperglycemia. It is now considered a worldwide pandemic. T2DM, a spectrum of diseases initially caused by tissue insulin resistance and slowly developing to a state characterized by absolute loss of secretory action of the β cells of the pancreas, is thought to be caused by reduced insulin secretion, resistance to tissue activities of insulin, or a combination of both. Insulin secretagogues, biguanides, insulin sensitizers, alpha-glucosidase ...
Source: Current Diabetes Reviews - October 27, 2023 Category: Endocrinology Authors: Abhishek Kumar Rupa Mazumder Anjna Rani Pratibha Pandey Navneet Khurana Source Type: research
Novel Approaches for the Management of Type 2 Diabetes Mellitus: An Update
Curr Diabetes Rev. 2023 Oct 5. doi: 10.2174/0115733998261903230921102620. Online ahead of print.ABSTRACTDiabetes mellitus is an irreversible, chronic metabolic disorder indicated by hyperglycemia. It is now considered a worldwide pandemic. T2DM, a spectrum of diseases initially caused by tissue insulin resistance and slowly developing to a state characterized by absolute loss of secretory action of the β cells of the pancreas, is thought to be caused by reduced insulin secretion, resistance to tissue activities of insulin, or a combination of both. Insulin secretagogues, biguanides, insulin sensitizers, alpha-glucosidase ...
Source: Current Diabetes Reviews - October 27, 2023 Category: Endocrinology Authors: Abhishek Kumar Rupa Mazumder Anjna Rani Pratibha Pandey Navneet Khurana Source Type: research
Novel Approaches for the Management of Type 2 Diabetes Mellitus: An Update
Curr Diabetes Rev. 2023 Oct 5. doi: 10.2174/0115733998261903230921102620. Online ahead of print.ABSTRACTDiabetes mellitus is an irreversible, chronic metabolic disorder indicated by hyperglycemia. It is now considered a worldwide pandemic. T2DM, a spectrum of diseases initially caused by tissue insulin resistance and slowly developing to a state characterized by absolute loss of secretory action of the β cells of the pancreas, is thought to be caused by reduced insulin secretion, resistance to tissue activities of insulin, or a combination of both. Insulin secretagogues, biguanides, insulin sensitizers, alpha-glucosidase ...
Source: Current Diabetes Reviews - October 27, 2023 Category: Endocrinology Authors: Abhishek Kumar Rupa Mazumder Anjna Rani Pratibha Pandey Navneet Khurana Source Type: research
Novel Approaches for the Management of Type 2 Diabetes Mellitus: An Update
Curr Diabetes Rev. 2023 Oct 5. doi: 10.2174/0115733998261903230921102620. Online ahead of print.ABSTRACTDiabetes mellitus is an irreversible, chronic metabolic disorder indicated by hyperglycemia. It is now considered a worldwide pandemic. T2DM, a spectrum of diseases initially caused by tissue insulin resistance and slowly developing to a state characterized by absolute loss of secretory action of the β cells of the pancreas, is thought to be caused by reduced insulin secretion, resistance to tissue activities of insulin, or a combination of both. Insulin secretagogues, biguanides, insulin sensitizers, alpha-glucosidase ...
Source: Current Diabetes Reviews - October 27, 2023 Category: Endocrinology Authors: Abhishek Kumar Rupa Mazumder Anjna Rani Pratibha Pandey Navneet Khurana Source Type: research
Novel Approaches for the Management of Type 2 Diabetes Mellitus: An Update
Curr Diabetes Rev. 2023 Oct 5. doi: 10.2174/0115733998261903230921102620. Online ahead of print.ABSTRACTDiabetes mellitus is an irreversible, chronic metabolic disorder indicated by hyperglycemia. It is now considered a worldwide pandemic. T2DM, a spectrum of diseases initially caused by tissue insulin resistance and slowly developing to a state characterized by absolute loss of secretory action of the β cells of the pancreas, is thought to be caused by reduced insulin secretion, resistance to tissue activities of insulin, or a combination of both. Insulin secretagogues, biguanides, insulin sensitizers, alpha-glucosidase ...
Source: Current Diabetes Reviews - October 27, 2023 Category: Endocrinology Authors: Abhishek Kumar Rupa Mazumder Anjna Rani Pratibha Pandey Navneet Khurana Source Type: research
Risk of Pancreatitis With Incretin Therapies Versus Thiazolidinediones in the Veterans Health Administration
CONCLUSION AND RELEVANCE: This retrospective cohort study of national VHA data found a relatively low incidence of pancreatitis in both cohorts, and an adjusted odds ratio found no statistical difference of pancreatitis in patients prescribed an incretin therapy compared with a control group. This data adds to growing evidence that incretin therapies do not seem to be associated with an increased risk of developing pancreatitis.PMID:37881914 | DOI:10.1177/10600280231205490 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - October 26, 2023 Category: Drugs & Pharmacology Authors: Kristen Wilhite Jennifer Meyer Reid Matthew Lane Source Type: research
From GLP1 receptor agonists to triple hormone receptor activation supplemented with glucagon receptor agonism.
Orv Hetil. 2023 Oct 22;164(42):1656-1664. doi: 10.1556/650.2023.32894. Print 2023 Oct 22.ABSTRACTFollowing the introduction of mono- and then dual hormone (incretin) receptor agonists into therapy, attention was turned to multiple receptor stimulation, with the additional activation of the glucagon receptor, as a new option for the pharmaceutical treatment of type 2 diabetes and obesity. In addition to its role in carbohydrate metabolism, the article reviews the other important physiological tasks of glucagon, especially its participation in intrainsular paracrine regulation, energy expenditure and the shaping of appetite ...
Source: Orvosi Hetilap - October 22, 2023 Category: General Medicine Authors: G ábor Winkler J ános Tibor Kis Krisztina Arapovicsn é Kiss L ászló Schandl Source Type: research
From GLP1 receptor agonists to triple hormone receptor activation supplemented with glucagon receptor agonism.
Orv Hetil. 2023 Oct 22;164(42):1656-1664. doi: 10.1556/650.2023.32894. Print 2023 Oct 22.ABSTRACTFollowing the introduction of mono- and then dual hormone (incretin) receptor agonists into therapy, attention was turned to multiple receptor stimulation, with the additional activation of the glucagon receptor, as a new option for the pharmaceutical treatment of type 2 diabetes and obesity. In addition to its role in carbohydrate metabolism, the article reviews the other important physiological tasks of glucagon, especially its participation in intrainsular paracrine regulation, energy expenditure and the shaping of appetite ...
Source: Orvosi Hetilap - October 22, 2023 Category: General Medicine Authors: G ábor Winkler J ános Tibor Kis Krisztina Arapovicsn é Kiss L ászló Schandl Source Type: research
From GLP1 receptor agonists to triple hormone receptor activation supplemented with glucagon receptor agonism.
Orv Hetil. 2023 Oct 22;164(42):1656-1664. doi: 10.1556/650.2023.32894. Print 2023 Oct 22.ABSTRACTFollowing the introduction of mono- and then dual hormone (incretin) receptor agonists into therapy, attention was turned to multiple receptor stimulation, with the additional activation of the glucagon receptor, as a new option for the pharmaceutical treatment of type 2 diabetes and obesity. In addition to its role in carbohydrate metabolism, the article reviews the other important physiological tasks of glucagon, especially its participation in intrainsular paracrine regulation, energy expenditure and the shaping of appetite ...
Source: Orvosi Hetilap - October 22, 2023 Category: General Medicine Authors: G ábor Winkler J ános Tibor Kis Krisztina Arapovicsn é Kiss L ászló Schandl Source Type: research
